Oaktree Acquisition Corp. III Life Sciences
NASDAQ:OACCShell Companies
+$0.00 today
- Market cap
- $263.53M
- Beta
- -0.04
- P/E (TTM)
- 29.1
- EPS (TTM)
- $0.37
Volume 0.00M
Average 0.01M
OACC Weighted Avg Shares
Average number of basic shares outstanding during the period, used to calculate basic EPS.
Oaktree Acquisition Corp. III Life SciencesNASDAQ: OACC
Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026
Weighted avg shares declines year over year
Q1 FY2026 weighted avg shares of 19.2M shares fell 21.9% year over year. Sequentially, it fell 21.9% from the prior quarter.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares history
Shares · from the income statement
- Latest · FY2025
- 19.2M USD
- Year-over-year change
- -21.9%
- 1-year CAGR
- -21.9%
| Period | Period end | Weighted Avg Shares | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 19.2M | -21.9% |
| FY2024 | 2024-12-31 | 24.58M | — |
Weighted Avg Shares vs competitors
How OACC compares with its peers on the latest reported figures
- OACC's LTM Mar 2026 weighted avg shares of 21.89M shares is the 8th highest of the 10 companies compared; the peer median is 24.75M shares.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | 27.4M | +9.0% | +8.5% | |
| LTM Mar 2026 | 26.54M | — | — | |
| LTM Mar 2026 | 26.01M | — | — | |
| LTM Mar 2026 | 25.76M | — | — | |
| LTM Mar 2026 | 24.75M | — | — | |
MBAVM3-Brigade Acquisition V Corp. Class A Ordinary shares | LTM Mar 2026 | 23.37M | -18.5% | — |
AACBArtius II Acquisition Inc. Class A Ordinary Shares | LTM Mar 2026 | 22.75M | — | — |
OACCOaktree Acquisition Corp. III Life Sciences | LTM Mar 2026 | 21.89M | — | — |
| LTM Mar 2026 | 21.4M | -13.9% | -18.8% | |
COPLCopley Acquisition Corp | LTM Mar 2026 | 15.91M | — | — |
| Peer median (excluding OACC) | 24.75M | -13.9% | -5.1% | |
Competitors are the stored peer set for OACC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Revenue | 0 | 0 |
| Cost of Revenue | 0 | 0 |
| Gross Profit | 0 | 0 |
| Gross Margin | — | — |
| Research & Development | 0 | 0 |
| Selling, General & Admin | 704 | 1.2M |
| Operating Expenses | 704 | 1.2M |
| Depreciation & Amortization | 704 | 0 |
| EBITDA | (351.81K) | (1.2M) |
| EBITDA Margin | — | — |
| Operating Income | (703) | (1.2M) |
| Operating Margin | — | — |
| Interest Income | 1.59M | 8.48M |
| Interest Expense | 0 | 0 |
| Other Income / Expenses | 3.37K | 8.48M |
| Income Before Tax | 2.66K | 7.29M |
| Pre-Tax Margin | — | — |
| Income Tax Expense | 0 | 0 |
| Net Income | 2.66K | 7.29M |
| Net Margin | — | — |
| EPS (Basic) | 0.05 | 0.30 |
| EPS (Diluted) | 0.05 | 0.30 |
| Weighted Avg Shares | 24.58M | 19.2M |
| Weighted Avg Shares (Diluted) | 24.58M | 19.2M |
Oaktree Acquisition Corp. III Life Sciences
NASDAQ:OACC
Intrinsic Alpha fair value
Locked
Current Price
$10.72
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.